Precision use of tranexamic acid for intracerebral hemorrhage
Official title: PRECISion usE of TRANexamic Acid for Supratentorial Acute Cerebral Hemorrhage Trial: a Pilot Randomized Controlled Trial
Run by The University of Hong Kong · NCT07365150 · Data updated 2026-11-12
This study will try giving intravenous tranexamic acid to adults with certain supratentorial intracerebral hemorrhages within 6 hours to see if it limits hematoma growth and improves recovery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 3 sites (Hong Kong and 2 other locations) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | June 30, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | January 26, 2026 |
| Trial ID | NCT07365150 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with primary supratentorial ICH presenting within 6 hours, GCS ≥8, meeting location-specific volume criteria and without contraindications to tranexamic acid are the intended candidates.
✕Probably not a fit
Patients with infratentorial hemorrhages, late presentation beyond 6 hours, significant pre-existing disability, anticoagulation use, planned surgery, or contraindications to tranexamic acid are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional protocol enrolls adults with primary supratentorial intracerebral hemorrhage who present within 6 hours and meet location-specific hematoma volume thresholds. Eligible participants receive intravenous tranexamic acid with the aim of reducing early hematoma expansion in patients at highest risk. The design intentionally enriches enrollment by ICH location and size to reduce outcome heterogeneity that has limited prior hemostatic trials. Key outcomes include hematoma growth and functional recovery measured during follow-up.
Why it matters
Potential benefit: If successful, targeted use of tranexamic acid could reduce hematoma expansion and translate into better neurological outcomes for selected ICH patients.
How similar studies have gone: Previous trials of tranexamic acid and other hemostatic agents often reduced hematoma expansion but generally failed to show clear improvements in functional outcomes, making this targeted approach relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Primary ICH Diagnosis * Age ≥ 18 years * Within 6 hours of ICH * Supratentorial ICH * GCS ≥8 * Location-specific volume criteria (\>7ml for thalamus or internal capsule; \>30ml for putamen or lobar) Exclusion Criteria: * Severe pre-morbid disability (Pre-morbid modified Rankin scale 5) * Anticipated surgical treatment * Recent acute atherosclerotic cardiovascular diseases (e.g. acute coronary syndrome, ischemic stroke) * Receiving anticoagulation * Recent intravascular stent placement and on dual antiplatelet treatment * Expected life expectancy of \<1 year * Inability to participate in follow-up activity * Bleeding tendency * Severe renal impairment * Severe liver impairment * Known contraindication or allergy to tranexamic acid
Where it's running
-
Prince of Wales Hospital
Hong Kong, Hong Kong Recruiting -
The University of Hong Kong
Hong Kong, Hong Kong Recruiting -
Pamela Youde Nethersole Eastern Hospital
Hong Kong, Hong Kong Not yet recruiting
Study contacts
- Study coordinator: Kay Cheong Teo, MBBS, MD
- Email: kcteo@hku.hk
- Phone: 852-22552368
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Smartphone-based EEG to detect hidden awareness in ICU patients with brain injuries
Researchers will test a smartphone-enabled EEG to see if it can reveal Cognitive Motor Dissociation in ICU patients who can’t show commands at bedside.
-
Chinese multicenter group studies spontaneous intracerebral hemorrhage in adults
This study tests how a large group of adults with spontaneous intracerebral hemorrhage (and a healthy control group) progress over time to understand outcomes and determinants of recovery.
-
Rapid Evacuation and Access of Cerebral Hemorrhage Registry: observing minimally invasive surgery outcomes
This registry collection tests how minimally invasive brain-bleed procedures work in real patients with acute spontaneous intracerebral hemorrhage.
-
Single triple-combination blood pressure pill after intracerebral hemorrhage
This trial tests whether a single pill combining amlodipine, valsartan, and hydrochlorothiazide helps adults who recently had an intracerebral hemorrhage control their blood pressure.
-
Vitamin D treatment after intracerebral hemorrhage
This will try giving higher-dose vitamin D to adults within 96 hours of an intracerebral hemorrhage to see if it helps clear the bleed faster and is safe.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.